Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

9.7%

3 terminated out of 31 trials

Success Rate

78.6%

-7.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

45%

5 of 11 completed with results

Key Signals

5 with results79% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (1)
P 1 (2)
P 2 (9)

Trial Status

Completed11
Recruiting8
Unknown5
Terminated3
Not Yet Recruiting2
Active Not Recruiting2

Trial Success Rate

78.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT00001971RecruitingPrimary

Evaluation of Patients With Liver Disease

NCT07491848Recruiting

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

NCT06504485RecruitingPrimary

Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment

NCT02577029Phase 2Terminated

Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

NCT06505928Phase 2Active Not RecruitingPrimary

A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D

NCT06740474Phase 1Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants

NCT04863703Active Not RecruitingPrimary

Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)

NCT07038863Not ApplicableNot Yet Recruiting

Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France

NCT05936073RecruitingPrimary

DELTA DESCRIBE: the French Collaborative Project

NCT06122285RecruitingPrimary

Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)

NCT06397859RecruitingPrimary

Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis

NCT06264583RecruitingPrimary

HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection

NCT06360484Completed

Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus

NCT05903742RecruitingPrimary

Standardising Care for Hepatitis Delta in the Netherlands

NCT05962307CompletedPrimary

Efficacy and Safety of Bulevirtide (BLV) Therapy in HDV Chronic Hepatitis (CHD) in Italy

NCT05928000UnknownPrimary

HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV

NCT05002907Completed

Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)

NCT05467553Phase 2UnknownPrimary

A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

NCT04847440Phase 2Terminated

A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

NCT05394623UnknownPrimary

Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)

Scroll to load more

Research Network

Activity Timeline